What question did this study set out to answer?

The aim is to validate pathology-based predictors of chemotherapy responsiveness in intermediate-risk luminal breast cancer patients.

February 8, 2026SHILAP Revista de lepidopterologíaOpen Access

A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population

View Full Paper

Ask AI

Bookmark

Authors

GLGuanhong LiAffiliated Hospital of Guizhou Medical University YZYuan ZengNanchang Institute of Technology YSYu SunHunan Normal University

Discussion

Member takes

Implication

This retrospective study validates histological grade and Ki67 index in predicting chemotherapy outcomes in intermediate-risk luminal breast cancer, suggesting effective clinical decision-making.

Key Points

The aim is to validate pathology-based predictors of chemotherapy responsiveness in intermediate-risk luminal breast cancer patients.
Retrospective analysis of surgically treated breast cancer patients.
Comparison of survival outcomes between chemotherapy-treated and untreated groups.
Use of propensity score matching to balance baseline characteristics.
Assessment of disease-free survival and overall survival using Kaplan–Meier and Cox regression analyses.
Histological grade 2–3, Ki67 index ≥20%, and absence of chemotherapy identified as independent risk factors for disease-free survival.
Chemotherapy significantly reduced recurrence risk in patients with Ki67 ≥20% and histological grade 2–3.
Ki67 index ≥20% was the only independent prognostic factor for overall survival, with no significant benefit from chemotherapy observed.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/698829410fc35cd7a88497bf https://doi.org/10.3389/fmed.2026.1727768

View Full Paper

Ask AI

Bookmark

Implication

This retrospective study validates histological grade and Ki67 index in predicting chemotherapy outcomes in intermediate-risk luminal breast cancer, suggesting effective clinical decision-making.

A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population

Discussion

Member takes

Implication

Key Points

Cite This Study

A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider